Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460731 | 0.94 | HSD17B10 (0.48) | HSD17B10ALDH1A1MAPTHTTTSHR | |
| SCHEMBL3462911 | 0.93 | ALDH1A1 (0.49) | HSD17B10ALDH1A1MAPTHTTTSHR | |
| SCHEMBL3461246 | 0.92 | KDM4E (0.49) | HSD17B10ALDH1A1MAPTHTTTSHR | |
| SCHEMBL3462243 | 0.88 | KMT2A (0.47) | HSD17B10ALDH1A1PARP1KDM4EL3MBTL1 | |
| SCHEMBL3459880 | 0.87 | FLT3 (0.44) | HSD17B10ALDH1A1MAPTHTTPARP1 | |
| SCHEMBL3461900 | 0.86 | KDM4E (0.55) | HSD17B10ALDH1A1HTTMAOASYK | |
| SCHEMBL3462887 | 0.84 | MAOB (0.51) | HSD17B10ALDH1A1MAPTMAOASYK | |
| SCHEMBL3459697 | 0.83 | HRH3 (0.45) | HSD17B10ALDH1A1MAPTKDM4EL3MBTL1 | |
| SCHEMBL13463747 | 0.81 | FLT3 (0.40) | HSD17B10ALDH1A1MAPTHTTPARP1 | |
| SCHEMBL13463380 | 0.81 | KDM4E (0.50) | HSD17B10ALDH1A1MAPTHTTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694057-B1 | LIPOXYGENASE INHIBITORS | STANFORD RES INST INT (US) | 2019-06-05 | — | — | EP | claimed |
| US-10646471-B2 | Lipoxygenase inhibitors | SRI INTERNATIONAL (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2694057-B1 | LIPOXYGENASE INHIBITORS | STANFORD RES INST INT (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170095450-A1 | Lipoxygenase Inhibitors | SRI INTERNATIONAL | 2017-04-06 | — | — | US | disclosed |
| EP-2326327-B1 | ANALOGS OF INDOLE-3-CARBINOL AND THEIR USE AS AGENTS AGAINST INFECTION | STANFORD RES INST INT (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2326327-B1 | ANALOGS OF INDOLE-3-CARBINOL AND THEIR USE AS AGENTS AGAINST INFECTION | STANFORD RES INST INT (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20130345214-A1 | Lipoxygenase Inhibitors | SRI INTERNATIONAL, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8399502-B2 | Analogs of indole-3-carbinol and their use as agents against infection | SRI INTERNATIONAL (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399502-B2 | Analogs of indole-3-carbinol and their use as agents against infection | SRI INTERNATIONAL (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120283240-A1 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection | SRI INTERNATIONAL | 2012-11-08 | — | — | US | disclosed |
| US-20120283240-A1 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection | SRI INTERNATIONAL | 2012-11-08 | — | — | US | disclosed |
| US-20120283240-A1 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection | SRI INTERNATIONAL | 2012-11-08 | — | — | US | disclosed |
| US-8278341-B2 | Analogs of indole-3-carbinol and their use as agents against infection | SRI INTERNATIONAL (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278341-B2 | Analogs of indole-3-carbinol and their use as agents against infection | SRI INTERNATIONAL (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278341-B2 | Analogs of indole-3-carbinol and their use as agents against infection | SRI INTERNATIONAL (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100069355-A1 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection | UNITED STATES GOVERNMENT; DEFENSE THREAT REDUCTION AGENCY | 2010-03-18 | — | — | US | disclosed |
| US-20100069355-A1 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection | UNITED STATES GOVERNMENT; DEFENSE THREAT REDUCTION AGENCY | 2010-03-18 | — | — | US | disclosed |
| US-20100069355-A1 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection | UNITED STATES GOVERNMENT; DEFENSE THREAT REDUCTION AGENCY | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095450-A1 | Lipoxygenase Inhibitors | ALOX15B, ALOX12, ALOX15 | HSD17B10 289/4885ALDH1A1 608/4885MAPT 436/4885 |
| US-20120283240-A1 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection | IDO1, IDO2, TDO2 | HSD17B10 1780/4885ALDH1A1 1789/4885MAPT 3994/4885 |
| US-20100069355-A1 | Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection | IDO1, IDO2, TDO2 | HSD17B10 1780/4885ALDH1A1 1789/4885MAPT 3994/4885 |
| US-20130345214-A1 | Lipoxygenase Inhibitors | ALOX15B, ALOX12, ALOX15 | HSD17B10 289/4885ALDH1A1 608/4885MAPT 436/4885 |
| US-10646471-B2 | Lipoxygenase inhibitors | ALOX15B, ALOX12, ALOX15 | HSD17B10 289/4885ALDH1A1 608/4885MAPT 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.